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Recently, the Trial to Evaluate Cardio-
vascular and Other Long-term Outcomes
With Semaglutide in Subjects With Type
2 Diabetes (SUSTAIN-6) suggested that
semaglutide may increase the risk for di-
abetic retinopathy (DR) adverse events
(AEs) comparedwith placebo. Other trials
of glucagon-like peptide 1 receptor ago-
nists (GLP-1RA) showed a numerically
higher incidence of DR AEs for liraglutide
but not exenatide. However, these trials
did not systematically assess DR. Our
population-based cohort study of older
U.S. adults suggested that GLP-1RA use
for approximately 1 year does not in-
crease DR risk (1). As current evidence on
GLP-1RA–associated DR risk is still limited,
we conducted a disproportionality analysis
of the U.S. Food and Drug Administration
(FDA) Adverse Event Reporting System
(FAERS) database to examine the associ-
ation between GLP-1RA and DR events.
We used generic and brand names to
identify GLP-1RA (exenatide, liraglutide,
albiglutide, and dulaglutide) and compar-
ator drugs in the FAERS database and
Medical Dictionary for Regulatory Activ-
ities (MedDRA v21.0) preferred terms to
identify DR cases (diabetic retinopathy,
retinopathy, macular edema, retinopathy
proliferative, retinopathy hemorrhagic,
blindness, vitreous hemorrhage) from
28 April 2005 (approval date for the first
GLP-1RA, exenatide) to 30 September
2017. We performed a disproportionality
analysis using the reporting odds ratio
(ROR) to assess whether there is a signal
for a potentially increased risk of DR
among GLP-1RA users. The ROR is calcu-
lated by dividing the odds of a DR event
reported for the drug of interest by the
odds of a DR event reported for the
comparison drugs. A signal was defined
as an ROR of$2. We analyzed data using
SAS 9.4 (SAS Institute Inc., Cary, NC).
We compared GLP-1RA versus five
groups (Fig. 1): 1) other glucose-lowering
drugs (GLDs) (metformin, sulfonylureas,
thiazolidinediones, sodium–glucose co-
transporter 2 inhibitors [SGLT2i], dipep-
tidyl peptidase 4 inhibitors, insulin,
a-glucosidase inhibitors, and glinides);
2) GLDs excluding insulin, as insulin has
an “early worsening” effect on DR; 3) two
classes of therapeutic alternativesd
thiazolidinediones (pioglitazone and ro-
siglitazone) and SGLT2i (canagliflozin,
dapagliflozin, and empagliflozin); 4)
SGLT2i, a newer class of GLD, as re-
porting of AEs is more frequent for
newer agents; and 5) all other drugs in
the database.We conducted a sensitivity
analysis for each comparison, restricting
to events where the treatment was re-
ported as “primary suspect” (those drugs
directly suspected of causing the AEs),
and then performed analyses stratified
by each GLP-1RA.
The FAERS database contained 389
DR cases associated with GLP-1RA, 197
of which were “primary suspect” cases.
The number of DR events associated
with exenatide, liraglutide, albiglutide,
and dulaglutide was 263, 82, 16, and
28, respectively. The ROR (95% CI) for
DR for the comparisons described above
were as follows: 1) 0.16 (0.14, 0.17); 2)
0.32 (0.28, 0.35); 3) 0.29 (0.26, 0.33); 4)
0.88 (0.71, 1.10); and 5) 0.72 (0.65, 0.80).
The results were consistent with the pri-
mary analyses when restricting to “primary
suspect” cases. Similarly, in the analyses
stratified by individual GLP-1RA, we saw
no signal of increased DR risk (Fig. 1).
Our analysis of the FAERS database
indicates that there is no signal for the
association between GLP-1RA and DR,
which is consistent with the Exenatide
Study of Cardiovascular Event Lowering
(EXSCEL) and Liraglutide Effect and Ac-
tion in Diabetes: Evaluation of Cardio-
vascular Outcome Results (LEADER) trials
and our recent cohort study (1). A recent
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FAERS analysis (2) comparing GLP-1RA
with other GLDs and stratified by insulin
also suggested no signal. We extend those
analyses with a comparison with thera-
peutic alternatives (thiazolidinediones
and SGLT2i), a comparison with a newer
agent (SGLT2i), and an analysis restricted
to “primary suspect” cases.
GLP-1RA have been reported to protect
retinal cells and retinal endothelium from
high-glucose–induced damage (3,4); the
topical use ofGLP-1RAhas beenproposed
as a possible therapy for DR (5). The un-
expected increase in DR AEs in SUSTAIN-
6 may be explained by rapid lowering
of blood glucose or a direct deleterious
effect of semaglutide (4). Unfortunately,
in our study, there was no available
semaglutide data, as the drug was ap-
proved by the FDA in December 2017.
Furthermore, this database will not be
ideal for future analysis because AE re-
porting is likely to be confounded by
greater attention to the potential issue
with semaglutide, given the SUSTAIN-6
results. Another possibility is that the
increased risk of retinopathy is limited to
subpopulations included in SUSTAIN-6
trials but not represented in our study.
Our analyses have limitations. Sponta-
neous events reporting is subject to re-
porting bias, lack of denominator data,
and confounding. Data on comorbidities,
previous treatment, or the duration of
treatment for the suspected drugs are
often missing. Overall, although the low
RORs suggest that GLP-1RA are not
associated with DR, further study is
needed.
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